Margaret Brivanlou Ph.D

Jan 22, 2025 | jdsupra.com | Margaret Brivanlou Ph.D |Peter A. Jaslow |Philip Legendy

Ballard Spahr attorneys from the firm’s Life Sciences and Health Care Industry Teams were on the ground in sunny San Francisco for the 43rd Annual J.P. Morgan Health Care Conference (#JPM25) January 12-15. The weather was vibrant and so was the atmosphere, with ample opportunity for networking and collaboration among prominent participants. KEY TAKEAWAYS: Cautious Optimism for Deal Making.

Jan 22, 2024 | jdsupra.com | Margaret Brivanlou Ph.D |Peter A. Jaslow |Philip Legendy

Ballard Spahr attorneys from the firm’s Life Sciences and Health Care Industry Teams were on the ground for the 42nd Annual J.P. Morgan Healthcare Conference (JPM24) from January 7-10. While still less crowded than pre-pandemic levels, there was a general air of optimism that had been missing last year and the discussions were as compelling as ever at the premier gathering of global industry leaders, emerging companies, technology creators, and the investment community.

May 23, 2023 | jdsupra.com | Caryn Borg-Breen |Scott D. Marty |Margaret Brivanlou Ph.D

On May 18, 2023, the Supreme Court decided Amgen Inc., et al. v. Sanofi, et al., No. 2-1757, unanimously affirming decisions of the Federal Circuit and the District of Delaware finding for respondents Sanofi and Regeneron that petitioner Amgen’s patent claims directed to a genus of antibodies are invalid for lack of enablement under 35 U.S.C. § 112(a). According to the Court, Amgen’s patent claims did not describe the full scope of the antibody genus according to its structure.